- Home
- SLND vs KYTX Comparison
SLND vs KYTX Comparison
Compare SLND & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- KYTX
- Stock Information
- Founded
- SLND 1900
- KYTX 2018
- Country
- SLND United States
- KYTX United States
- Employees
- SLND N/A
- KYTX N/A
- Industry
- SLND Military/Government/Technical
- KYTX
- Sector
- SLND Industrials
- KYTX
- Exchange
- SLND Nasdaq
- KYTX NYSE
- Market Cap
- SLND 188.8M
- KYTX 166.4M
- IPO Year
- SLND N/A
- KYTX 2024
- Fundamental
- Price
- SLND $3.49
- KYTX $3.37
- Analyst Decision
- SLND Buy
- KYTX Buy
- Analyst Count
- SLND 2
- KYTX 5
- Target Price
- SLND $5.50
- KYTX $23.20
- AVG Volume (30 Days)
- SLND 43.5K
- KYTX 308.0K
- Earning Date
- SLND 03-03-2025
- KYTX 02-12-2025
- Dividend Yield
- SLND N/A
- KYTX N/A
- EPS Growth
- SLND N/A
- KYTX N/A
- EPS
- SLND N/A
- KYTX N/A
- Revenue
- SLND $1,029,117,999.00
- KYTX N/A
- Revenue This Year
- SLND N/A
- KYTX N/A
- Revenue Next Year
- SLND $6.18
- KYTX N/A
- P/E Ratio
- SLND N/A
- KYTX N/A
- Revenue Growth
- SLND N/A
- KYTX N/A
- 52 Week Low
- SLND $1.85
- KYTX $3.22
- 52 Week High
- SLND $6.16
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- SLND 52.51
- KYTX 37.34
- Support Level
- SLND $3.28
- KYTX $3.22
- Resistance Level
- SLND $3.59
- KYTX $3.53
- Average True Range (ATR)
- SLND 0.22
- KYTX 0.25
- MACD
- SLND 0.00
- KYTX 0.00
- Stochastic Oscillator
- SLND 42.25
- KYTX 13.46
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.